ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
16
views
0
references
Top references
cited by
116
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
4,004
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Author(s):
Chungyeul Kim
,
Soonmyung Paik
,
Norman Wolmark
Publication date:
2008-03-27
Journal:
The New England journal of medicine
Keywords:
Antibodies, Monoclonal
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
genetics
,
metabolism
,
Chemotherapy, Adjuvant
,
Female
,
Gene Amplification
,
Genes, erbB-2
,
Humans
,
RNA, Messenger
,
Receptor, ErbB-2
,
immunology
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
open (via free article)
Powered by
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
A Sustainable Future
Author and article information
Journal
PubMed ID::
18367751
DOI::
10.1056/NEJMc0801440
ScienceOpen disciplines:
Chemistry
Keywords:
Antibodies, Monoclonal
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
genetics
,
metabolism
,
Chemotherapy, Adjuvant
,
Female
,
Gene Amplification
,
Genes, erbB-2
,
Humans
,
RNA, Messenger
,
Receptor, ErbB-2
,
immunology
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Antibodies, Monoclonal
,
therapeutic use
,
Antibodies, Monoclonal, Humanized
,
Antineoplastic Agents
,
Breast Neoplasms
,
drug therapy
,
genetics
,
metabolism
,
Chemotherapy, Adjuvant
,
Female
,
Gene Amplification
,
Genes, erbB-2
,
Humans
,
RNA, Messenger
,
Receptor, ErbB-2
,
immunology
Comments
Comment on this article
Sign in to comment
scite_
Similar content
4,004
Effect of electrolytes as adjuvants in GFP and LPS partitioning on aqueous two-phase systems: 1. Polymer-polymer systems
Authors:
Sandro Roberto Valentini
,
Valéria dos Santos-Ebinuma
,
Jorge Pereira
…
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Authors:
M. Gnant
,
M Filipits
,
R Greil
…
HER2 splice site mutation c.1899-1G>A as the potential acquired resistance to trastuzumab in a patient with HER2-positive gastric adenocarcinoma
Authors:
X-D Jiao
,
K LIU
,
Y. Wu
…
See all similar
Cited by
112
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Authors:
Jeffrey Ross
,
Elzbieta Slodkowska
,
W Symmans
…
Deconstructing the molecular portraits of breast cancer
Authors:
Aleix Prat
,
Charles Perou
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
Authors:
François-Clément Bidard
,
Tanja Fehm
,
Michail Ignatiadis
…
See all cited by